참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Dimethylformamide | HCID 6228 | — |
| 반응물 | Hydrazine | HCID 9321 | — |
| 반응물 | DMA dimethylacetamide | HCID 19097097 | — |
| 반응물 | 4-Methyl-2-(2-(quinoxalin-5-yl)acetamido)thiophene-3-carboxamide | HCID 68756207 | — |
| 생성물 | HCID 178434590 | HCID 178434590 | — |
반응 단계
This analog was made from 4-methyl-2-(2-(quinoxalin-5-yl)acetamido)thiophene-3-carboxamide using protocol D except that the DMF was also used in the DMA-DMA step with heating to 95° C. (rather than 110° C.) and the hydrazine step was heated at 95° C. (rather than 90° C.). Method[7], MS (ESI) 365.1 [M+H], Retention time=3.58 min; 1H-NMR (300 MHz, CDCl3) δ 11.9 (s, 1H), 8.87 (s, 2H), 8.17-8.14 (m, 1H), 7.92-7.83 (m, 2H), 6.50 (s, 1H), 4.53 (s, 2H), 2.45 (s, 3H), 2.30 (s, 3H).
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US08450363B2 |
|---|
| 출처 데이터셋 | uspto-grants-2013_05 |
|---|
| ORD ID | ord-e6ea72bba4ad40ffb6ae644b902c7a86 |
|---|
| 출처 메모 | uspto-grants-2013_05 |
|---|
